论文部分内容阅读
为验证麦普替林对癌症患者抑郁倩绪的疗效．本研究采用双盲对照研究，对55例癌症术后有明显抑郁情绪的患者采用麦普替林50～100mg／日治疗，观察4周。以抑郁自评量表（SDS）及疗效后评量表（CGI）及患者自觉效果判定，评定疗效、不良反应症状量表（TESS），评定不良反应，结果显示实验组SDS减分值、减分率及疗效指数明显高于对照组，自觉显效率96％，对照组别为21％。两组有明显差异，提示麦普替林对癌症患者的抑郁情绪有明显疗效。
To verify the efficacy of Maiputiin on depression in cancer patients. In this study, a double-blind controlled study was conducted with 50 to 100 mg/day of matoplatin in 55 patients with significant post-operative depression, and observed for 4 weeks. The efficacy and adverse reaction symptoms (TESS) were evaluated by the Self-Rating Depression Scale (SDS), the CGI, and the patient’s self-consciousness. The adverse reactions were evaluated. The results showed that the experimental group had SDS scores, minus Scores and efficacy index were significantly higher than the control group, consciously significant efficiency 96%, control group was 21%. There was a significant difference between the two groups, suggesting that pircetate has a significant effect on the depressive mood of cancer patients.